cetuximab (Erbitux)

Advice

In the absence of a submission from the holder of the marketing authorisation.

cetuximab (Erbitux) is not recommended for use within NHS Scotland for the treatment of patients with squamous cell cancer of the head and neck in combination with platinumbased chemotherapy for recurrent and/or metastatic disease.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.